Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, Flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I or Class II HLA antigens
CPT4 code
Name of the Procedure:
Antibody to Human Leukocyte Antigens (HLA), Solid Phase Assays (e.g., Microspheres or Beads, ELISA, Flow Cytometry); Qualitative Assessment of the Presence or Absence of Antibody(ies) to HLA Class I or Class II HLA Antigens.
Summary
This procedure tests for the presence of antibodies against human leukocyte antigens (HLAs), which are proteins on the surface of cells that help regulate the immune system. The test can use various methods such as microspheres or beads, ELISA (enzyme-linked immunosorbent assay), and flow cytometry to determine if these antibodies are present or absent.
Purpose
The test is often used in the context of organ transplantation, autoimmune diseases, and certain infections. The goal is to identify if a person's immune system is likely to reject a donor organ or if they have antibodies that might be causing other health issues.
Indications
- Pre-transplant screening for organ transplant compatibility.
- Evaluation of potential graft rejection.
- Diagnosis and management of autoimmune diseases.
- Investigation of unexplained inflammation or immune responses.
Preparation
- No specific preparation is usually required.
- Inform your healthcare provider of any medications you are taking.
- A blood sample is typically needed; refer to the test site for specific instructions.
Procedure Description
- Sample Collection: A blood sample is taken from the patient.
- Sample Processing: The blood sample is processed to isolate the antibodies.
- Testing: The sample is tested using one of several methods:
- Microspheres or Beads: Tiny synthetic beads coated with HLA antigens are mixed with the sample. Binding of antibodies to the antigens on the beads indicates the presence of HLA antibodies.
- ELISA: The sample is added to a plate with HLA antigens and an enzyme-linked antibody that produces a color change if HLA antibodies are present.
- Flow Cytometry: Cells with HLA antigens are mixed with the sample and passed through a laser beam; binding of antibodies is detected by changes in light patterns.
- Qualitative Assessment: The presence or absence of HLA antibodies is determined based on the test results.
Duration
The procedure itself is quick, taking only a few minutes for blood collection. The overall process, including analysis, may take several hours to a few days.
Setting
The procedure is typically performed in a hospital laboratory or a specialized diagnostic clinic.
Personnel
- Phlebotomist (for blood sample collection)
- Medical laboratory technologist (for sample processing and testing)
- Immunologist or pathologist (for interpreting results)
Risks and Complications
- Blood draw risks: minor bruising or discomfort at the needle site.
- Laboratory processing risks: minimal to none, as the test is non-invasive.
Benefits
- Helps in determining organ transplant compatibility.
- Aids in diagnosing and managing autoimmune diseases.
- Provides critical information for preventing graft rejection.
Recovery
- No specific recovery is needed post-blood draw.
- Normal activities can be resumed immediately.
Alternatives
- Crossmatch testing (to further assess compatibility in organ transplantation).
- Panel reactive antibody (PRA) testing.
- Genetic testing for HLA typing.
Patient Experience
- During the blood draw, a slight pinch or discomfort may be felt.
- After the procedure, instructions are usually minimal, focusing on monitoring the puncture site for any signs of infection or prolonged bleeding.
- Pain management is generally not required beyond basic first aid measures if needed.